Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1856

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1B
Chunk 1856
---
 to be done by virtue hereof.

Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following
persons on behalf of the Registrant in the capacities and on the dates indicated.

    Name
     
    Title
     
    Date

    /s/ Chris Ehrlich
     
    Chairman and Chief Executive Officer and Director
     
    April 15, 2025
  
    Chris Ehrlich
     
    (Principal Executive Officer)

    /s/ Andrew Kucharchuk
     
    Chief Financial Officer
     
    April 15, 2025
  
    Andrew Kucharchuk
     
    (Principal Financial and Accounting Officer)

    /s/ Brian Atwood
     
    Director
     
    April 15, 2025
  
    Brian Atwood

    /s/ Michael Byrnes
     
    Director
     
    April 15, 2025
  
    Michael Byrnes

    /s/ Kathleen LaPorte
     
    Director
     
    April 15, 2025
  
    Kathleen LaPorte

    /s/ Shami Patel
     
    Director
     
    April 15, 2025
  
    Shami Patel

    /s/ Lindsey Rolfe
     
    Director
     
    April 15, 2025
  
    Lindsey Rolfe

118

CERO THERAPEUTICS HOLDINGS, INC.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 2024 and 2023

  Report of Independent Registered Public Accounting Firm (PCAOB ID No. 392)   F-2  Consolidated Balance Sheets as of December 31, 2024 (Successor) and December 31, 2023 (Predecessor)   F-3  Consolidated Statements of Operations for the periods from January 1, 2024 to February 13, 2024 (Predecessor) and February 14, 2024 to December 31, 2024 (Successor) and for the year ended December 31, 2023 (Predecessor)   F-4  Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the
periods from January 1, 2024 to February 13,